Teleflex (NYSE:TFX) Stock Rating Upgraded by Wall Street Zen

Teleflex (NYSE:TFX) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a note issued to investors on Saturday.

Several other research analysts have also commented on TFX. Bank of America upgraded Teleflex from an “underperform” rating to a “neutral” rating and set a $135.00 price target for the company in a research report on Monday, April 13th. Weiss Ratings restated a “sell (d)” rating on shares of Teleflex in a report on Wednesday. Wells Fargo & Company raised their price target on Teleflex from $130.00 to $138.00 and gave the stock an “equal weight” rating in a research report on Friday, May 8th. Mizuho set a $140.00 price objective on shares of Teleflex in a research note on Friday, May 8th. Finally, Piper Sandler upgraded shares of Teleflex from a “neutral” rating to an “overweight” rating and raised their target price for the stock from $140.00 to $160.00 in a report on Monday, June 8th. Four investment analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $146.00.

Teleflex Price Performance

Shares of NYSE:TFX opened at $129.57 on Friday. The firm has a market cap of $5.74 billion, a price-to-earnings ratio of -5.68, a P/E/G ratio of 0.95 and a beta of 0.82. The firm has a fifty day moving average price of $130.03 and a 200 day moving average price of $119.67. Teleflex has a fifty-two week low of $100.18 and a fifty-two week high of $139.67. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.03 and a current ratio of 2.55.

Teleflex (NYSE:TFX) last announced its quarterly earnings results on Thursday, May 7th. The medical technology company reported $1.39 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.21 by $0.18. Teleflex had a negative net margin of 35.88% and a positive return on equity of 13.29%. The company had revenue of $548.30 million for the quarter, compared to the consensus estimate of $536.91 million. During the same period in the previous year, the firm posted $1.44 EPS. Teleflex’s revenue for the quarter was up 32.3% compared to the same quarter last year. Teleflex has set its FY 2026 guidance at 6.250-6.550 EPS. As a group, sell-side analysts expect that Teleflex will post 6.7 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Teleflex

Hedge funds and other institutional investors have recently modified their holdings of the stock. Banque Cantonale Vaudoise boosted its stake in Teleflex by 82.5% in the 4th quarter. Banque Cantonale Vaudoise now owns 250 shares of the medical technology company’s stock worth $31,000 after purchasing an additional 113 shares in the last quarter. V Square Quantitative Management LLC purchased a new position in shares of Teleflex in the fourth quarter worth $37,000. UMB Bank n.a. raised its holdings in shares of Teleflex by 57.1% in the fourth quarter. UMB Bank n.a. now owns 311 shares of the medical technology company’s stock worth $38,000 after buying an additional 113 shares during the last quarter. Sound Income Strategies LLC acquired a new stake in shares of Teleflex during the fourth quarter worth $45,000. Finally, Kestra Advisory Services LLC acquired a new stake in shares of Teleflex during the fourth quarter worth $45,000. 95.62% of the stock is owned by hedge funds and other institutional investors.

Teleflex Company Profile

Teleflex Incorporated is a diversified global provider of medical technologies, specializing in critical care and surgery. Headquartered in Wayne, Pennsylvania, the company designs, manufactures and distributes devices and solutions used by healthcare professionals in hospital, ambulatory and alternate site settings. Teleflex focuses on delivering products that support complex interventional procedures and improve patient outcomes.

The company’s offerings span several key segments, including Interventional Urology, Respiratory & Anesthesia, Surgical, Cardiac Care, Vascular and Original Equipment Manufacturer (OEM) solutions.